Atopic Dermatitis Market Poised for Phenomenal Expansion During the Forecast Period (2023-32) - Estimates DelveInsight | Allakos, AnaptysBio, AOBiome, Argenx, Eli Lilly, GI Innovation, Intrinsic Medicine, Merck, Pfizer, Qurient Co, Reistone, Teres Bio

The Atopic Dermatitis market size in the 7MM was approximately USD 15,650 million in 2022 and it is projected to increase at a significant CAGR during the forecast period (2023-2032). The Atopic Dermatitis Market is set to register immense growth in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the diseases, and incremental healthcare spending across the world. Several major key players such as Amgen, Kyowa Kirin, Dermira, Eli Lilly and Company, Almirall, Dermavant Sciences, Japan Tobacco Pharmaceutical, Torii Pharmaceutical, and others, are actively working in the Atopic Dermatitis therapeutics market to improve the treatment scenario.

DelveInsight's "Atopic Dermatitis Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Atopic Dermatitis Market Size and Share in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The market report covers emerging drugs, treatment practices, market share of individual Atopic Dermatitis therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Atopic Dermatitis treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.

Atopic Dermatitis: An Overview
Atopic dermatitis (AD), also known as atopic eczema, is a type of inflammation of the skin (dermatitis). It results in itchy, red, swollen, and cracked skin. Clear fluid may come from the affected areas, which often thickens over time. While the condition may occur at any age, it typically starts in childhood, with changing severity over the years. In children under one year of age, much of the body may be affected. As children get older, the back of the knees and the front of the elbows are the most common areas affected. In adults, the hands and feet are the most commonly affected areas. Scratching worsens symptoms and affected people have an increased risk of skin infections. Many people with atopic dermatitis develop hay fever or asthma.

Those who live in cities and dry climates are more commonly affected. Exposure to certain chemicals or frequent handwashing makes symptoms worse. While emotional stress may make the symptoms worse. The disorder is not contagious. The diagnosis is typically based on the signs and symptoms.

Atopic Dermatitis Market Key Facts
• The market size in the 7MM will increase at a CAGR of 7.8% due to increasing awareness of the disease and the launch of the emerging therapy.
• Among EU4 countries, the United Kingdom accounts for the maximum market size in 2022, while Spain occupied the bottom of the ladder in 2022.
• The total prevalent cases of Atopic Dermatitis in the United States were around 32,573,900 cases in 2022.
• The US contributed to the largest prevalent population of Atopic Dermatitis, acquiring ~45% of the 7MM in 2022. Whereas Japan accounted for around 13%, and the United Kingdom accounted for around 10% of the total population share, respectively, in 2022.
• Among EU4 countries, the United Kingdom accounted for the largest number of Atopic Dermatitis cases, followed by France, whereas Spain accounted for the lowest number of cases in 2022.
• As per DelveInsight, in the US, JAK inhibitors (OPZELURA [ruxolitinib], RINVOQ [upadacitinib], CIBINQO [abrocitinib], CORECTIM [delgocitinib], and OLUMIANT [baricitinib]) will garner a market share of ~USD 2,650 million by 2032.

Discover How Atopic Dermatitis Market Will Grow by 2032:
https://www.delveinsight.com/report-store/atopic-dermatitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Atopic Dermatitis Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Atopic Dermatitis therapies in the market. It also provides a detailed assessment of the Atopic Dermatitis market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete detail of the market trend for each marketed Atopic Dermatitis drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MOA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Atopic Dermatitis Epidemiology
The epidemiology section covers detailed insights into the historical, and current Atopic Dermatitis patient pool and forecasted epidemiology trends for every seven major countries (7MM) from 2019 to 2032.

The Report Covers the Atopic Dermatitis Epidemiology Segmented as -
• Prevalent Cases of Atopic Dermatitis in the 7MM (2019-2032)
• Gender-specific Prevalence of Atopic Dermatitis in Adults in the 7MM (2019-2032)
• Severity-specific distribution of Atopic Dermatitis in Adults in 7MM (2019-2032)
• Diagnosed Prevalent Cases of Atopic Dermatitis in the 7MM (2019-2032)
• Severity-specific distribution of Atopic Dermatitis in Pediatric Population in 7MM (2019-2032)

Get Key Insights Into the Evolving Atopic Dermatitis Epidemiology Trends @
https://www.delveinsight.com/report-store/atopic-dermatitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Atopic Dermatitis Drugs Uptake and Pipeline Development Activities
The drugs' uptake section focuses on the rate of uptake of the potential drugs recently launched in the Atopic Dermatitis market or expected to be launched during the study period. The analysis covers the market share by Atopic Dermatitis drugs, patient uptake by therapies, and sales of each drug.

The report's drugs uptake section helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It allows the comparison of the drugs based on market share and size, which again will be helpful in investigating factors important in understanding the market dynamics and in making financial and regulatory decisions.

The report also covers the Atopic Dermatitis Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Latest Clinical, Commercial, and Regulatory Developments in the Atopic Dermatitis Therapeutics Market
• May 23, 2023, TrialSpark, Inc. announced that the first patient has been dosed in its Phase 2 clinical trial for ASN008-201, a topical sodium channel blocker in development for pruritus associated with atopic dermatitis (AD). This clinical trial is a randomized, double-blind, vehicle-controlled, Phase 2 trial to evaluate the anti-pruritic efficacy, safety, tolerability, and pharmacokinetics of ASN008 in adults with mild to moderate AD (NCT05870865). Topline data for this trial is expected in 2024.
• On May 23 2023, Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) announced enrollment of the first patient in the Phase 2 clinical trial of orally administered RASP modulator ADX 629, an investigational new drug, for the treatment of atopic dermatitis.
• On February 10, 2023, Pfizer Inc. (NYSE: PFE) announced that the United States (U.S.) Food and Drug Administration (FDA) approved its supplemental New Drug Application (sNDA) for CIBINQO® (abrocitinib), expanding its indication to include adolescents with refractory, moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with other systemic drug products, including biologics, or when the use of those therapies is inadvisable. CIBINQO was previously approved only for the treatment of adults 18 years and older.

Explore More About Ongoing Pipeline Development Activities @
https://www.delveinsight.com/sample-request/atopic-dermatitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Atopic Dermatitis Therapeutics Assessment
Several major pharma and biotech companies are developing therapies for Atopic Dermatitis. Currently, Dermavant Sciences is leading the therapeutics market with its Atopic Dermatitis drug candidates in the most advanced stage of clinical development.

Leading Companies in the Atopic Dermatitis Therapeutics Market Include
Akaal Pharma, Allakos Inc., Alphyn Biologics, AnaptysBio, AOBiome, Arcutis Biotherapeutics, Argenx, Dermavant Sciences, E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd., Eli Lilly and Company, Genome & Company, GI Innovation, Hangzhou Yirui Pharmaceutical Technology Co., Ltd, Intrinsic Medicine, Kiniksa Pharmaceuticals, MC2 therapeutics, Merck Sharp & Dohme LLC, Pfizer, Qurient Co, Reistone Biopharma, Selection, Shulov Innovate for Science, Sun Pharmaceutical, Suzhou Connect Biopharmaceuticals, Teres Bio, TWi Biotechnology, Vanda Pharmaceuticals, and many others.

Emerging and Marketed Atopic Dermatitis Drugs Covered in the Report Include:
• Tapinarof: Dermavant Sciences
• Etrasimod: Pfizer
• B244: AOBiome
• Lirentelimab: Allakos Inc.
• QY201: E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.
• Rocatinlimab: Amgen/Kyowa Kirin
• Lebrikizumab: Dermira/Eli Lilly and Company/Almirall
• VTAMA: Dermavant Sciences/ Japan Tobacco Pharmaceutical/ Torii Pharmaceutical
And Many Others

Learn More About the Emerging Therapies & Key Companies in the Atopic Dermatitis Therapeutics Market:
https://www.delveinsight.com/sample-request/atopic-dermatitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Atopic Dermatitis Competitive Intelligence Analysis
4. Atopic Dermatitis Market Overview at a Glance
5. Atopic Dermatitis Background and Overview
6. Atopic Dermatitis Patient Journey
7. Atopic Dermatitis Epidemiology and Patient Population
8. Atopic Dermatitis Treatment Algorithm, Current Treatment, and Medical Practices
9. Atopic Dermatitis Unmet Needs
10. Key Endpoints of Atopic Dermatitis Treatment
11. Atopic Dermatitis Marketed Products
12. Atopic Dermatitis Emerging Therapies
13. Atopic Dermatitis Seven Major Market Analysis
14. Attribute Analysis
15. Atopic Dermatitis Market Outlook (7 major markets)
16. Atopic Dermatitis Access and Reimbursement Overview
17. KOL Views on the Atopic Dermatitis Market.
18. Atopic Dermatitis Market Drivers
19. Atopic Dermatitis Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.

Download the Sample PDF to Get Detailed Insights About the Report's Offerings @
https://www.delveinsight.com/sample-request/atopic-dermatitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

-------------------------------------------- xx --------------------------------------------
Other Trending Healthcare Reports by DelveInsight
Preeclampsia Market
https://www.delveinsight.com/report-store/preeclampsia-market

Chronic Periodontitis Market
https://www.delveinsight.com/report-store/chronic-periodontitis-market

Cryptococcosis Market
https://www.delveinsight.com/report-store/cryptococcosis-market

Exocrine Pancreatic Insufficiency Market
https://www.delveinsight.com/report-store/exocrine-pancreatic-insufficiency-market

Papilloma MarketRespiratory Distress Syndrome Market
https://www.delveinsight.com/report-store/respiratory-distress-syndrome-market

Sinusitis Market
https://www.delveinsight.com/report-store/sinusitis-market

Childhood Atropine For Myopia Progression Market
https://www.delveinsight.com/report-store/childhood-atropine-for-myopia-progression-market

Cushing's Syndrome Market
https://www.delveinsight.com/report-store/cushings-syndrome-market

Skin Burns Market
https://www.delveinsight.com/report-store/skin-burns-market

Adeno-Associated Virus Vectors in Gene Therapy Market
https://www.delveinsight.com/report-store/adeno-associated-virus-vectors-in-gene-therapy-market

Autism Spectrum Disorder Market
https://www.delveinsight.com/report-store/autism-spectrum-disorder-asd-market

Fragile X Syndrome (FXS) Market
https://www.delveinsight.com/report-store/fragile-x-syndrome-fxs-market

Lymphedema Market
https://www.delveinsight.com/report-store/lymphedema-market

Optic Neuropathy Market
https://www.delveinsight.com/report-store/optic-neuropathy-market

Nicotine Addiction MarketDiverticulitis Market
https://www.delveinsight.com/report-store/diverticulitis-market

Sinus Dilation Devices Market
https://www.delveinsight.com/report-store/sinus-dilation-devices-market

Von Willebrand disease (VWD) Market
https://www.delveinsight.com/report-store/von-willebrand-disease-vwd-market

Type 2 Diabetes Market
https://www.delveinsight.com/report-store/type-2-diabetes-market

Bone Resorption Market
https://www.delveinsight.com/report-store/bone-resorption-market

Peptic Ulcers Market
https://www.delveinsight.com/report-store/peptic-ulcers-market

Castration-Resistant Prostate Cancer (CRPC) Market
https://www.delveinsight.com/report-store/castration-resistant-prostate-cancer-crpc-market

Dysmenorrhea Market
https://www.delveinsight.com/report-store/dysmenorrhea-market

HDAC Inhibitors Market
https://www.delveinsight.com/report-store/hdac-inhibitors-market

Iron Deficiency Anemia Market
https://www.delveinsight.com/report-store/iron-deficiency-anemia-market

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market
https://www.delveinsight.com/report-store/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market

Myelodysplastic Syndrome Market
https://www.delveinsight.com/report-store/myelodysplastic-syndrome-market

Sacral Nerve Stimulator Devices Market
https://www.delveinsight.com/report-store/sacral-nerve-stimulator-devices-market

Graft Versus Host Disease Market
https://www.delveinsight.com/report-store/graft-versus-host-disease-gvhd-market

Traumatic Brain Injury Market
https://www.delveinsight.com/report-store/traumatic-brain-injury-market

Artificial Disc Market
https://www.delveinsight.com/report-store/artificial-disc-market

Corneal Endothelial Dystrophy Market
https://www.delveinsight.com/report-store/corneal-endothelial-dystrophy-market

Bone Neoplasms Market
https://www.delveinsight.com/report-store/bone-neoplasms-market

Duchenne Muscular Dystrophy Market
https://www.delveinsight.com/report-store/duchenne-muscular-dystrophy-market

Secondary Hyperparathyroidism Market
https://www.delveinsight.com/report-store/secondary-hyperparathyroidism-market

Fetal Monitoring Devices Market
https://www.delveinsight.com/report-store/fetal-monitoring-devices-market

Relapsing Multiple Sclerosis (RMS) Market
https://www.delveinsight.com/report-store/relapsing-multiple-sclerosis-rms-market

Interspinous Spacers Market
https://www.delveinsight.com/report-store/interspinous-spacers-market

Cerebral Palsy Market
https://www.delveinsight.com/report-store/cerebral-palsy-market

Glioblastoma Market
https://www.delveinsight.com/report-store/glioblastoma-market

Breast Pumps Market
https://www.delveinsight.com/report-store/breast-pumps-market

Diabetic Peripheral Neuropathy Market
https://www.delveinsight.com/report-store/diabetic-peripheral-neuropathy-market

Throat Cancer Market
https://www.delveinsight.com/report-store/throat-cancer-market

Osteoporosis Market
https://www.delveinsight.com/report-store/osteoporosis-market

Implantable Cardioverter Defibrillators (ICDs) Market
https://www.delveinsight.com/report-store/implantable-cardioverter-defibrillators-icds-market

Open-Angle Glaucoma Market
https://www.delveinsight.com/report-store/open-angle-glaucoma-market

Prurigo Nodularis Market
https://www.delveinsight.com/report-store/prurigo-nodularis-market

Contact Info:
Shruti Thakur
Manager (Marketing & Branding)
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.